MARKET WIREYahoo Finance • 1d ago
TELA Bio to Announce Third Quarter 2026 Financial ResultsYahoo Finance report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
Why TELA Stock slipped -1.33% Today — RQD Quant Desk Flash
$0.80 -1.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.80
TELA Bio Inc. (TELA) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $36.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on TELA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TELA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, TELA Bio Inc. (NASDAQ: TELA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.80 (-1.33% 1D, market cap $36.6M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TELA ranks #603 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TELA compare to CVRX and NEPH in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), TELA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of -35.0%. By comparison, CVRX (CVRx Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M) and NEPH (Nephros Inc.) posts a C- grade (59/100 RQD, P/E 29.8x, ROIC 18.9%, cap $34.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TELA?
▼
Per TELA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001561921), TELA Bio Inc. generated $80.3M in revenue (+15.8% YoY), -$38.8M in net income, and -$28.7M in free cash flow against $81.4M in total assets and $55.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.80 (-0.43%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw D- · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-10% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TELA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY TELA SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 67.7% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+9/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Macro Regime Fit4/20 pts (-16 pt drag)
Macro rate sensitivity & RSI-14 (37.6) create a -16 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.07+1.9% Next Q
43
Q2 (-2Q)Grade D$1.09-11.9% Next Q
40
Q3 (-1Q)Grade E$0.96-16.7% Next Q
38
CurrentGrade D-$0.80-8.5% Hist 90D α
35
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TELA Turnaround Squeeze
While TELA currently carries a cautious 35/100 (D-) rating due to Macro Regime Fit (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.02) and Max Pain ($0.84) forces dealer call-delta covering toward $1.58.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TELA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TELA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TELA Stock slipped -1.33% Today — RQD Quant Desk Flash
TELA Bio Inc. (TELA) slipped -1.33% to $0.80, trading at 30% of its 52-week range ($0.5 – $1.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 30% of its 52-week range ($0.5 – $1.5) with RSI-14 at 37.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.80 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 67.7% gross margin and $0 annual free cash flow.
Live TELA Headlines & Catalysts
MARKET WIREInvesting.com UK • 1d ago
Form 4 Tela Bio Inc: Joseph H. Capper (Director) For: 15 OctoberInvesting.com UK report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Stock replaces cash pay for TELA Bio (TELA) director in 19,801-share award.Stock Titan report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue ReinforcementYahoo Finance report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREQuiver Quantitative • 1d ago
TELA Bio Receives FDA 510(k) Clearance for Liora Monofilament Scaffold, Expanding Soft-Tissue Reconstruction PortfolioQuiver Quantitative report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
The FDA cleared a surgical mesh designed to be fully absorbed by the body.Stock Titan report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.siam.in/ • 1d ago
TELA Bio Q2 2026 Earnings: Loss per Share Comes In Wider Than Analysts Modeled, Yet Shares Edge Higher - Surprise Factor Analysishttps://www.siam.in/ report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 2d ago
TELA Bio Q2 2026 Earnings: Wider-Than-Expected Loss Sends Shares Down 11.96% - Earnings Quality Scorehttps://www.dars.gov.et/ report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 15d ago
TELA Bio (TELA) Stock Sees Fair Value Cut As Analysts Weigh New Leadership RisksThe fair value estimate for TELA Bio has shifted from US$2.25 to US$1.90, which points to a lower assessed price target based on the latest analyst work. This reset lines up with a split analyst view, where some see new
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TELA)
- ✓Walkthrough of TELA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TELA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.61%📐 HORIZONTAL RANGE
2026-11-03O $0.92H $0.92L $0.80C $0.80VOL 330.1K
RES: $1.70SUP: $0.50SMA50: $1.02SMA200: $0.86
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TELA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +15.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on TELA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TELA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TELA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TELA)
Health Care Rank #603 of 1015
⚔️ CVRX vs TELA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TELA vs. CVRX, NEPH, XTNT, DAVI)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, TELA Bio Inc. (TELA) ranks #603 by composite RQD confidence (35/100, grade D-) and #778 by equity capitalization ($36.6M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. XTNT currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with TELA at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TELA
ACTIVE
TELA Bio Inc. | D- | 35/100 | — | 67.7% | -35.0% | -1.33% | $36.6M | Benchmark Subject |
| CVRX CVRx Inc. | E | 31/100 | — | 85.3% | -35.0% | -2.84% | $37.6M | /cvrx-vs-tela → |
| NEPH Nephros Inc. | C- | 59/100 | 29.8x | 61.9% | 18.9% | +2.21% | $34.5M | /neph-vs-tela → |
| XTNT Xtant Medical Holdings Inc. | C | 65/100 | — | 62.9% | 12.8% | -0.64% | $39.3M | /xtnt-vs-tela → |
| DAVI Davion Healthcare Plc | D | 47/100 | — | — | — | -11.31% | $42.0M | /davi-vs-tela → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001561921 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), TELA Bio Inc. (TELA) reported GAAP revenue of $80.3M (+15.8% vs. FY2024 revenue of $69.3M , and +37.3% cumulative change since FY2023) , GAAP net income of -$38.8M, operating cash flow of -$28.2M, and free cash flow of -$28.7M (+32.7% YoY). On the balance sheet, TELA closed FY2025 with $81.4M in total assets against $55.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $80.3M | -$38.8M | -$28.2M | -$28.7M | $81.4M | $55.7M |
| FY2024 (FY) | 2024-12-31 | $69.3M | -$37.8M | -$41.6M | -$42.6M | $86.6M | $41.1M |
| FY2023 (FY) | 2023-12-31 | $58.5M | -$46.7M | -$40.9M | -$40.9M | — | — |
3. TELA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TELA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, TELA Bio Inc. (NASDAQ: TELA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.80 (-1.33% 1D, market cap $36.6M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TELA ranks #603 in composite RQD confidence.
How does TELA compare to CVRX and NEPH in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), TELA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of -35.0%. By comparison, CVRX (CVRx Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M) and NEPH (Nephros Inc.) posts a C- grade (59/100 RQD, P/E 29.8x, ROIC 18.9%, cap $34.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TELA?
Per TELA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001561921), TELA Bio Inc. generated $80.3M in revenue (+15.8% YoY), -$38.8M in net income, and -$28.7M in free cash flow against $81.4M in total assets and $55.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TELA trading relative to its 50-day, 200-day, and 52-week technical levels?
TELA last traded at $0.80 (-1.33% on volume of 165,257 shares), positioning the stock -21.57% below its 50-day simple moving average ($1.02) and -6.98% below its 200-day simple moving average ($0.86). Across its 52-week range of $0.50 to $1.50, TELA sits at the 30.0% percentile with a 14-day RSI of 37.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.90).
ROARABLE RATING BRIEF • RQD 35/100 (D-)
✓ SEC XBRL & RQD VERIFIED
TELA — TELA Bio Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
TELA Bio Inc. (TELA) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.80 (-1.33% 1D, market capitalization $36.6M).
- Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 67.7%, operating margin of -42.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (4/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of 8.50x.
2. Business Model, Unit Margins & SEC Financial Trajectory
TELA Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. Its market capitalization is $0.0B. Per the news wire, the company has received FDA 510(k) clearance for its Liora Monofilament Scaffold, described as a soft-tissue reinforcement product, which suggests its product line centers on surgical implant-type devices. Revenue figures are reported in the financials section.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), TELA Bio Inc. (TELA) reported $80.3M in annual revenue (up from $69.3M in FY2024, +15.8% YoY) and -$38.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($58.5M revenue, -$46.7M net income) through FY2025, TELA scaled operating cash flow to -$28.2M and free cash flow to -$28.7M, backed by $81.4M in total assets against $55.7M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.50 – $1.50 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -42.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
A prospective investor should note that the absence of mapped dependencies is itself a gap: the company's reliance on specific component suppliers, surgical-channel customers, or reimbursement pathways cannot be assessed from these sources. The only sector-level context available is the Health Care / Medical-Dental Instruments classification and the beta of 1.0.
- Key Question #1: Can TELA sustain or expand its -42.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $80.3M and free cash flow of -$28.7M, how will capital allocation balance growth reinvestment against $55.7M in total debt?
- Key Question #3: How sensitive is TELA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
TELA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for TELA Bio Inc. (TELA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 1d ago
TELA Bio to Announce Third Quarter 2026 Financial Results Yahoo Finance report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 1d ago
Form 4 Tela Bio Inc: Joseph H. Capper (Director) For: 15 October Investing.com UK report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Stock replaces cash pay for TELA Bio (TELA) director in 19,801-share award. Stock Titan report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement Yahoo Finance report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Quiver Quantitative • 1d ago
TELA Bio Receives FDA 510(k) Clearance for Liora Monofilament Scaffold, Expanding Soft-Tissue Reconstruction Portfolio Quiver Quantitative report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
The FDA cleared a surgical mesh designed to be fully absorbed by the body. Stock Titan report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.siam.in/ • 1d ago
TELA Bio Q2 2026 Earnings: Loss per Share Comes In Wider Than Analysts Modeled, Yet Shares Edge Higher - Surprise Factor Analysis https://www.siam.in/ report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 2d ago
TELA Bio Q2 2026 Earnings: Wider-Than-Expected Loss Sends Shares Down 11.96% - Earnings Quality Score https://www.dars.gov.et/ report covering TELA Bio Inc. (TELA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
TELA Bull vs. Bear Conversation Board — What's Your Call at $0.80?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TELA 🐻 33% BEARISH CONVICTION
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH
🎯 Target: $1.00 (+23.5%)
📌 Pinned Debate FDA 510(k) clearance for the Liora Monofilament Scaffold gives the company a fresh regulatory catalyst to support revenue growth from $
Here is why I am bullish on TELA here at $0.81: FDA 510(k) clearance for the Liora Monofilament Scaffold gives the company a fresh regulatory catalyst to support revenue growth from $58.5M to $80.3M over FY 2023–FY 2025.. Compare TELA's -42.0% operating margin and -35.0% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $0.77 are getting bought.
EarningsSniper 🐂 BULL
@SkepticalCFA Shorting a 8/20 institutional whale-flow stock at $0.81 is dangerous when funds are rotating into Health Care.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $0.62 (-23.5%)
Spot @ $0.81 With FY 2025 free cash flow of -$28.7M, debt rising to $55.7M against $50.8M of cash, and a Piotroski F-Score of 4/9, the balance sheet
Sitting on the sidelines or leaning short TELA above $0.81. With FY 2025 free cash flow of -$28.7M, debt rising to $55.7M against $50.8M of cash, and a Piotroski F-Score of 4/9, the balance sheet is under visible pressure.. Until Fundamental Cash Engine (9/20) and FCF yield (0.0%) inflect higher, upside is capped near $1.50.